AGS‑499
Amyotrophic Lateral Sclerosis (ALS)
PreclinicalActive
Key Facts
Indication
Amyotrophic Lateral Sclerosis (ALS)
Phase
Preclinical
Status
Active
About Neuromagen Pharma
Telomerase‑activating therapeutics for neurodegeneration and systemic age‑related disorders.
View full company profileAbout Neuromagen Pharma
Telomerase‑activating therapeutics for neurodegeneration and systemic age‑related disorders.
View full company profileAbout Neuromagen Pharma
Telomerase‑activating therapeutics for neurodegeneration and systemic age‑related disorders.
View full company profileAbout Neuromagen Pharma
Telomerase‑activating therapeutics for neurodegeneration and systemic age‑related disorders.
View full company profileAbout Neuromagen Pharma
Telomerase‑activating therapeutics for neurodegeneration and systemic age‑related disorders.
View full company profileAbout Neuromagen Pharma
Telomerase‑activating therapeutics for neurodegeneration and systemic age‑related disorders.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis (ALS) Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT520-34 | Neuropore Therapies | Pre-clinical/Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Phase 2/3 (Platform Trial) |
| CNM-Au8 | Clene | Phase 2/3 |
| Masitinib | AB Science | Phase 3 |
| SLS-005 | Seelos Therapeutics | Platform Trial |
| PMN442 | ProMIS Neurosciences | Preclinical |
| nAV-101 | nVector | Pre-clinical |
| ALTA-808 | Alteron Therapeutics | Preclinical |
| GM6 | Genervon Biopharmaceuticals | Phase 2 |
| Lou Gehrig’s disease | Genclis | Discovery |
| Treg-directed therapy for ALS | Iltoo Pharma | Pre-clinical |
| NG CELL | NeuroGenesis Bio | Phase 2 |